MedPath

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase 3
Completed
Conditions
Crohn Disease
Interventions
Other: Placebo
Registration Number
NCT03440385
Lead Sponsor
Celgene
Brief Summary

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
606
Inclusion Criteria
  • Crohn's disease for ≥ 3 months on endoscopy and on histological exam
  • Inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy
  • Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450
  • Average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points
  • Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≥ 6 (or SES-CD ≥ 4 in participants with isolated ileal disease)
Exclusion Criteria
  • Diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis, or has strictures with prestenotic dilatation requiring procedural intervention
  • Extensive small bowel resection (>100cm) or known diagnosis of short bowel syndrome, or requires total parenteral nutrition
  • Current stoma, ileal-anal pouch anastomosis, or fistula

Other protocol-defined inclusion/exclusion criteria apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Administration of PlaceboPlacebo-
Administration of oral OzanimodOzanimod-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150Week 12

The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Abdominal Pain and Stool Frequency Clinical RemissionWeek 12

Abdominal pain and stool frequency clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤ 3 with abdominal pain and stool frequency no worse than baseline at Week 12. Participants entered the responses in diaries daily. The 7 days entries prior to Week 12 visit were considered for calculating average abdominal pain score and stool frequency. The abdominal pain was graded on severity of 0 (none) to 3 (severe) scale and stool frequency was defined number of liquid or soft stools per day. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

Percentage of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50%Week 12

The SES-CD assessed the degree of inflammation. The SES-CD assesses the following 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater degree of inflammation. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

Percentage of Participants With Reduction From Baseline in the Crohn's Disease Activity Index (CDAI) Score of >= 100 Points or a Total CDAI Score < 150Week 12

The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

Percentage of Participants With a Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of ≥ 50%Week 12

CDEIS is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon. The CDEIS divides the intestine into 5 segments: rectum, sigmoid and left colon, transverse colon, right colon, and ileum. Four variables are assessed in each segment: the presence of deep ulceration, the presence of superficial ulceration, the percentage of ulcerated surface, and the percentage of surface affected by CD, indicated on 10-cm visual analogue scales. In addition, the presence of ulcerated stenosis and the presence of nonulcerated stenosis are also assessed over the entire intestine. These factors are weighted and summed to calculate the total score ranging from 0- 44, with higher scores indicating more severe disease.

Percentage of Participants With Abdominal Pain (AP) and Stool Frequency (SF) Clinical Remission and an Endoscopic (50%) ResponseWeek 12

AP and SF clinical remission is average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤ 3 times with AP and SF no worse than baseline at Week 12. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day. SES-CD has 4 components size of ulcers, ulcerated surface, affected surface, presence of narrowing. Each component was scored on scale of 0 (none) to 3 (worst). Endoscopic Response is defined as \>= 50% decrease from baseline in SES-CD. In SES-CD, each of 4 components are assessed in five segments: ileum, right, transverse, left colon, and rectum. The SES-CD was sum of individual scores of each of components across five segments. Range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for overall, with larger scores show greater degree of inflammation.

Percentage of Participants With Robarts Histologic Index (RHI) Mucosal Healing at Week 12Week 12

RHI mucosal healing was defined as RHI remission combined with SES-CD \<= 4 points and a SES-CD decrease from baseline \>= 2 points with no SES-CD sub-score \>1 point. RHI Remission is defined as no active inflammation in any measured segment. The SES-CD assesses the following 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 (none/unaffected) to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater degree of inflammation.

Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 and SES-CD Decrease From Baseline of ≥ 50%Week 12

CDAI include 8 components number of soft/liquid stools, severity of abdominal pain, wellbeing, complications, need antidiarrheal drugs, abdominal mass, hematocrit, deviation in body wt. Subscores of numbers of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to visit. The others weighted to create the total CDAI score ranging 0-600 with higher score indicating worse outcome. The SES-CD has 4 components size of ulcers, ulcerated surface, affected surface, presence of narrowing. Each component was scored on scale of 0 (none) to 3 (worst). In SES-CD, each of 4 components are assessed in the five segments: ileum, right, transverse, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for overall, with larger scores show greater degree of inflammation.

Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50%Week 12

CDAI include 8 components number of soft/liquid stools, severity of abdominal pain, wellbeing, complications, need antidiarrheal drugs, abdominal mass, hematocrit, deviation in body wt. Subscores of numbers of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to visit. The others weighted to create the total CDAI score ranging 0-600 with higher score indicating worse outcome. The SES-CD has 4 components size of ulcers, ulcerated surface, affected surface, presence of narrowing. Each component was scored on scale of 0 (none) to 3 (worst). In SES-CD, each of 4 components are assessed in the five segments: ileum, right, transverse, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for overall, with larger scores show greater degree of inflammation.

Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission and a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score <= 4 Points and Decrease >= 2 PointsWeek 12

Abdominal pain (AP) and stool frequency (SF) clinical remission was defined as average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤ 3 times with AP and SF no worse than baseline at Week 12. Participants entered responses in diaries daily. The 7 days entries prior to visit were considered for calculating average AP score and SF. The AP was graded on severity of 0 (none) to 3 (severe) scale and SF was defined number of liquid or soft stools per day. The SES-CD has 4 components size of ulcers, ulcerated surface, affected surface, presence of narrowing. Each component was scored on scale of 0 (none) to 3 (worst). In SES-CD, each of 4 components are assessed in the five segments: ileum, right, transverse, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for overall, with larger scores show greater degree of inflammation.

Percentage of Participants With Global Histologic Activity Score (GHAS) RemissionWeek 12

GHAS assesses the inflammation and mucosal damage. GHAS has 8 components Epithelial damage, Architectural changes, Infiltration of mononuclear cells in the lamina propria, Infiltration of polymorphonuclear cells in the lamina propria, Polymorphonuclear cells in epithelium, Presence of erosion and/or ulcers, Presence of granuloma and number of biopsy specimens affected. Each of these components was scored on a scale of 0 (none/unaffected) to 2 (worst). Each of these 8 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. Within each segment, the GHAS score has a range of 0 - 16, and the total GHAS score has a range of 0 - 80. Higher numbers correspond to more inflammation and more mucosal damage. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

Percentage of Participants With CDAI Reduction From Baseline of >=70 PointsWeek 12

The CDAI is a composite score that is used to measure the clinical activity of Crohn's disease (CD). The CDAI uses a questionnaire with 8 disease activity variables: number of soft/liquid stools, severity of abdominal pain, general well-being, presence of complications, need for antidiarrheal drugs, presence of an abdominal mass, hematocrit, and deviation in body weight. The sub scores of number of soft/liquid stool, severity of abdominal pain (0 \[none\] to 3 \[Severe\]), general well-being (0 \[well\] to 4 \[terrible\] were summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration.

Percentage of Participants With Absence of Ulcers ≥ 0.5 cm With no Segment With Any Ulcerated Surface ≥10%Week 12

The ulcerated surface were assessed via endoscopy.

Trial Locations

Locations (368)

Local Institution - 614

🇫🇮

Turku, Finland

Local Institution - 202

🇺🇸

Scottsdale, Arizona, United States

Ucsd Medical Center

🇺🇸

La Jolla, California, United States

Local Institution - 010

🇺🇸

Lancaster, California, United States

Southern California Research Institute Medical Group, Inc.

🇺🇸

Los Angeles, California, United States

Matrix Clinical Research Inc

🇺🇸

Los Angeles, California, United States

Facey Medical Foundation (Parent)

🇺🇸

Mission Hills, California, United States

Local Institution - 093

🇺🇸

Pasadena, California, United States

Sutter Medical Group

🇺🇸

Roseville, California, United States

Local Institution - 280

🇺🇸

Sacramento, California, United States

Local Institution - 281

🇺🇸

San Francisco, California, United States

Local Institution - 124

🇺🇸

West Covina, California, United States

Local Institution - 065

🇺🇸

Colorado Springs, Colorado, United States

Local Institution - 182

🇺🇸

Bristol, Connecticut, United States

Local Institution - 166

🇺🇸

Clearwater, Florida, United States

Local Institution - 084

🇺🇸

Clermont, Florida, United States

American Research Institute Inc

🇺🇸

Cutler Bay, Florida, United States

Local Institution - 112

🇺🇸

Doral, Florida, United States

Riverside Clinical Research

🇺🇸

Edgewater, Florida, United States

SIH Research

🇺🇸

Kissimmee, Florida, United States

Local Institution - 067

🇺🇸

Lighthouse Point, Florida, United States

Center For Advanced Gastroenterology

🇺🇸

Maitland, Florida, United States

Local Institution - 044

🇺🇸

Miami Springs, Florida, United States

LMG Research

🇺🇸

Miami, Florida, United States

Local Institution - 175

🇺🇸

Miami, Florida, United States

Local Institution - 081

🇺🇸

Miami, Florida, United States

Local Institution - 192

🇺🇸

New Port Richey, Florida, United States

Local Institution - 200

🇺🇸

Orlando, Florida, United States

Local Institution - 002

🇺🇸

Palmetto Bay, Florida, United States

Theia Clinical Research, LLC

🇺🇸

Pinellas Park, Florida, United States

Precision Clinical Research, LLC.

🇺🇸

Sunrise, Florida, United States

Local Institution - 183

🇺🇸

Tampa, Florida, United States

Apex Clinical Research

🇺🇸

Tampa, Florida, United States

Local Institution - 107

🇺🇸

Tampa, Florida, United States

Local Institution - 037

🇺🇸

Atlanta, Georgia, United States

Local Institution - 220

🇺🇸

Atlanta, Georgia, United States

Local Institution - 143

🇺🇸

Decatur, Georgia, United States

Local Institution - 115

🇺🇸

Idaho Falls, Idaho, United States

Local Institution - 022

🇺🇸

Chicago, Illinois, United States

Local Institution - 092

🇺🇸

Evansville, Indiana, United States

Local Institution - 033

🇺🇸

Indianapolis, Indiana, United States

Local Institution - 070

🇺🇸

Topeka, Kansas, United States

Local Institution - 020

🇺🇸

Baton Rouge, Louisiana, United States

Clinical Trials of SW Louisiana LLC

🇺🇸

Lake Charles, Louisiana, United States

Tandem Clinical Research, LLC

🇺🇸

Marrero, Louisiana, United States

Local Institution - 024

🇺🇸

Worcester, Massachusetts, United States

Local Institution - 054

🇺🇸

Hartsdale, New York, United States

Weill Cornell Medical College

🇺🇸

New York, New York, United States

Concorde Medical Group

🇺🇸

New York, New York, United States

TrialSpark

🇺🇸

New York, New York, United States

Local Institution - 167

🇺🇸

Kalamazoo, Michigan, United States

Local Institution - 005

🇺🇸

Novi, Michigan, United States

Local Institution - 095

🇺🇸

Minneapolis, Minnesota, United States

Local Institution - 045

🇺🇸

Rochester, Minnesota, United States

Local Institution - 198

🇺🇸

Kansas City, Missouri, United States

Local Institution - 040

🇺🇸

Lebanon, New Hampshire, United States

Internal Medicine Specialists

🇺🇸

Las Vegas, Nevada, United States

Local Institution - 060

🇺🇸

North Massapequa, New York, United States

Local Institution - 156

🇺🇸

Charlotte, North Carolina, United States

Local Institution - 052

🇺🇸

Winston-Salem, North Carolina, United States

Local Institution - 170

🇺🇸

Dayton, Ohio, United States

Local Institution - 049

🇺🇸

Hilliard, Ohio, United States

Paramount Medical Research & Consulting, Llc

🇺🇸

Middleburg Heights, Ohio, United States

Local Institution - 087

🇺🇸

Norman, Oklahoma, United States

Local Institution - 294

🇺🇸

Oklahoma City, Oklahoma, United States

Local Institution - 185

🇺🇸

Tulsa, Oklahoma, United States

Local Institution - 217

🇺🇸

Tulsa, Oklahoma, United States

University of Pennsylvania Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Local Institution - 034

🇺🇸

Fort Sam Houston, Texas, United States

Local Institution - 079

🇺🇸

Houston, Texas, United States

Local Institution - 196

🇺🇸

Houston, Texas, United States

Gulf Coast Research Group LLC

🇺🇸

Houston, Texas, United States

Accurate Clinical Research Inc

🇺🇸

Pasadena, Texas, United States

Local Institution - 071

🇺🇸

Richardson, Texas, United States

Local Institution - 178

🇺🇸

San Antonio, Texas, United States

Local Institution - 181

🇺🇸

Temple, Texas, United States

Local Institution - 292

🇺🇸

Riverton, Utah, United States

Local Institution - 030

🇺🇸

Lynchburg, Virginia, United States

The Gastroenterology Group

🇺🇸

Reston, Virginia, United States

Local Institution - 072

🇺🇸

Richmond, Virginia, United States

Local Institution - 172

🇺🇸

Roanoke, Virginia, United States

Local Institution - 089

🇺🇸

La Crosse, Wisconsin, United States

Local Institution - 309

🇦🇺

Liverpool, New South Wales, Australia

Local Institution - 318

🇦🇺

New Lambton Heights, New South Wales, Australia

Local Institution - 328

🇦🇺

Herston, Queensland, Australia

Local Institution - 313

🇦🇺

Maroorchydore, Queensland, Australia

Local Institution - 321

🇦🇺

North Mackay, Queensland, Australia

Local Institution - 312

🇦🇺

South Brisbane, Queensland, Australia

Local Institution - 307

🇦🇺

Bedford Park, South Australia, Australia

Local Institution - 326

🇦🇺

Elizabeth Vale, South Australia, Australia

Local Institution - 317

🇦🇺

Clayton, Victoria, Australia

Local Institution - 305

🇦🇺

Fitzroy, Victoria, Australia

Local Institution - 329

🇦🇺

Geelong, Victoria, Australia

Local Institution - 327

🇦🇺

Melbourne, Victoria, Australia

Local Institution - 315

🇦🇺

Subiaco, Western Australia, Australia

Local Institution - 726

🇦🇹

Innsbruck, Austria

Local Institution - 727

🇦🇹

St Polten, Austria

Local Institution - 336

🇦🇹

Vienna, Austria

Local Institution - 725

🇦🇹

Vienna, Austria

Local Institution - 753

🇧🇬

Ruse, Bulgaria

Local Institution - 750

🇧🇬

Sofia, Bulgaria

Local Institution - 755

🇧🇬

Sofia, Bulgaria

Local Institution - 756

🇧🇬

Sofia, Bulgaria

Local Institution - 752

🇧🇬

Sofia, Bulgaria

Local Institution - 554

🇧🇬

Sofia, Bulgaria

Local Institution - 269

🇨🇦

Edmonton, Alberta, Canada

Local Institution - 262

🇨🇦

New Westminister, British Columbia, Canada

Local Institution - 267

🇨🇦

Vancouver, British Columbia, Canada

Local Institution - 256

🇨🇦

Brandon, Manitoba, Canada

Local Institution - 266

🇨🇦

Sudbury, Ontario, Canada

Local Institution - 264

🇨🇦

Toronto, Ontario, Canada

Local Institution - 257

🇨🇦

Toronto, Ontario, Canada

Local Institution - 254

🇨🇦

Montreal, Quebec, Canada

Local Institution - 270

🇨🇦

Ottawa, Quebec, Canada

Local Institution - 423

🇨🇳

Changzhou City, Jiangsu, China

Local Institution - 369

🇨🇳

Shanghai, Shanghai, China

Local Institution - 482

🇨🇳

Beijing, China

Local Institution - 467

🇨🇳

Beijing, China

Local Institution - 379

🇨🇳

Bengbu, China

Local Institution - 485

🇨🇳

Changchun, China

Local Institution - 376

🇨🇳

Changchun, China

Local Institution - 421

🇨🇳

Changsha, China

Local Institution - 378

🇨🇳

Changsha, China

Local Institution - 414

🇨🇳

Changzhou, China

Local Institution - 419

🇨🇳

Chengdu, China

Local Institution - 422

🇨🇳

Fuzhou, China

Local Institution - 472

🇨🇳

Guangzhou Shi, China

Local Institution - 486

🇨🇳

Guangzhou Shi, China

Local Institution - 478

🇨🇳

Guangzhou, China

Local Institution - 470

🇨🇳

Hangzhou, Zhejiang, China

Local Institution - 491

🇨🇳

Hefei, China

Local Institution - 374

🇨🇳

Kunming, China

Local Institution - 383

🇨🇳

Luzhou, China

Local Institution - 488

🇨🇳

Nanchang, China

Local Institution - 418

🇨🇳

Nanjing City, China

Local Institution - 375

🇨🇳

Nanjing, China

Local Institution - 487

🇨🇳

Nanjing, China

Local Institution - 473

🇨🇳

Shanghai, China

Local Institution - 380

🇨🇳

Shanghai, China

Local Institution - 377

🇨🇳

Shanghai, China

Local Institution - 458

🇨🇳

Taichung City, China

Local Institution - 373

🇨🇳

Tianjin, China

Local Institution - 483

🇨🇳

Wuhan Shi, China

Local Institution - 475

🇨🇳

Wuhan, China

Local Institution - 474

🇨🇳

Wuhan, China

Local Institution - 381

🇨🇳

Wuxi, China

Local Institution - 415

🇨🇳

Xi'an, China

Local Institution - 420

🇨🇳

Xi'an, China

Local Institution - 370

🇨🇳

Zhengzhou, China

Local Institution - 397

🇨🇴

Armenia, Colombia

Local Institution - 398

🇨🇴

Barranquilla, Colombia

Local Institution - 395

🇨🇴

Bogota, Colombia

Local Institution - 396

🇨🇴

Cali, Colombia

Local Institution - 394

🇨🇴

Medellin, Colombia

Local Institution - 613

🇫🇮

Helsinki, Finland

Local Institution - 647

🇫🇷

Neuilly-sur-Seine, Cedex, France

Local Institution - 635

🇫🇷

Blois Cedex, France

Local Institution - 639

🇫🇷

Béziers, France

Local Institution - 634

🇫🇷

Caen, France

Local Institution - 644

🇫🇷

Colombes, France

Local Institution - 632

🇫🇷

Nantes, France

Local Institution - 630

🇫🇷

Pierre-Benite, France

Local Institution - 631

🇫🇷

Saint Priest en Jarez, France

Local Institution - 786

🇬🇪

Batumi, Georgia

Local Institution - 779

🇬🇪

Kutaisi, Georgia

Local Institution - 454

🇬🇪

Tbilisi, Georgia

Local Institution - 778

🇬🇪

Tbilisi, Georgia

Local Institution - 782

🇬🇪

Tbilisi, Georgia

Local Institution - 552

🇬🇪

Tbilisi, Georgia

Local Institution - 793

🇬🇪

Tbilisi, Georgia

Local Institution - 740

🇬🇪

Tbilisi, Georgia

Local Institution - 783

🇬🇪

Tbilisi, Georgia

Local Institution - 784

🇬🇪

Tbilisi, Georgia

Local Institution - 785

🇬🇪

Tbilisi, Georgia

Local Institution - 335

🇬🇪

Tbilisi, Georgia

Local Institution - 455

🇬🇪

Tbilisi, Georgia

Local Institution - 781

🇬🇪

Tbilisi, Georgia

Local Institution - 780

🇬🇪

Telavi, Georgia

Local Institution - 629

🇩🇪

Berlin, Germany

Local Institution - 648

🇩🇪

Berlin, Germany

Local Institution - 653

🇩🇪

Berlin, Germany

Local Institution - 628

🇩🇪

Berlin, Germany

Local Institution - 664

🇩🇪

Brandenburg an der Havel, Germany

Local Institution - 732

🇩🇪

Dachau, Germany

Local Institution - 574

🇩🇪

Frankfurt am Main, Germany

Local Institution - 657

🇩🇪

Frankfurt am Main, Germany

Local Institution - 658

🇩🇪

Halle, Germany

Local Institution - 656

🇩🇪

Halle, Germany

Local Institution - 652

🇩🇪

Hamburg, Germany

Local Institution - 591

🇩🇪

Hannover, Germany

Local Institution - 649

🇩🇪

Keil, Germany

Local Institution - 337

🇩🇪

Leipzig, Germany

Local Institution - 660

🇩🇪

Mainz, Germany

Local Institution - 667

🇩🇪

Muenster, Germany

Local Institution - 620

🇩🇪

Neuruppin, Germany

Local Institution - 584

🇩🇪

Nuertingen, Germany

Local Institution - 661

🇩🇪

Stuttgart, Germany

Local Institution - 592

🇬🇷

Athens, Attiki, Greece

Local Institution - 790

🇬🇷

Athens, Greece

Local Institution - 588

🇬🇷

Athens, Greece

Local Institution - 791

🇬🇷

Athens, Greece

Local Institution - 792

🇬🇷

Athens, Greece

Local Institution - 787

🇬🇷

Heraklion, Greece

Local Institution - 789

🇬🇷

Thessaloniki, Greece

Local Institution - 788

🇬🇷

Thessaloniki, Greece

Local Institution - 404

🇭🇰

Hong Kong, Hong Kong

Local Institution - 405

🇭🇰

Kowloon, Hong Kong

Local Institution - 798

🇭🇺

Bekescsaba, Hungary

Local Institution - 803

🇭🇺

Budapest, Hungary

Local Institution - 804

🇭🇺

Budapest, Hungary

Local Institution - 556

🇭🇺

Budapest, Hungary

Local Institution - 801

🇭🇺

Gyor, Hungary

Local Institution - 555

🇭🇺

Gyula, Hungary

Local Institution - 797

🇭🇺

Miskolc, Hungary

Local Institution - 800

🇭🇺

Nagykanizsa, Hungary

Local Institution - 799

🇭🇺

Szekesfehervar, Hungary

Local Institution - 816

🇭🇺

Szekszárd, Hungary

Local Institution - 805

🇭🇺

Szentes, Hungary

Local Institution - 343

🇮🇱

Afula, Israel

Local Institution - 346

🇮🇱

Beer Jacob, Israel

Local Institution - 350

🇮🇱

Haifa, Israel

Local Institution - 347

🇮🇱

Jerusalem, Israel

Local Institution - 349

🇮🇱

Kfar-Saba, Israel

Local Institution - 341

🇮🇱

Petah Tikva, Israel

Local Institution - 340

🇮🇱

Tel-Aviv, Israel

Local Institution - 434

🇰🇷

Busan, Korea, Republic of

Local Institution - 431

🇰🇷

Busan, Korea, Republic of

Local Institution - 432

🇰🇷

Daegu, Korea, Republic of

Local Institution - 438

🇰🇷

Seoul, Korea, Republic of

Local Institution - 429

🇰🇷

Suwon, Korea, Republic of

Local Institution - 605

🇱🇹

Kaunas, Lithuania

Local Institution - 603

🇱🇹

Klaipeda, Lithuania

Local Institution - 607

🇱🇹

Vilnius, Lithuania

Local Institution - 606

🇱🇹

Vilnius, Lithuania

Local Institution - 604

🇱🇹

Vilnius, Lithuania

Local Institution - 952

🇳🇱

Amsterdam, Netherlands

Local Institution - 955

🇳🇱

Amsterdam, Netherlands

Local Institution - 956

🇳🇱

Groningen, Netherlands

Local Institution - 949

🇳🇱

Nijmegen, Netherlands

Local Institution - 951

🇳🇱

Sittard-Geleen, Netherlands

Local Institution - 954

🇳🇱

Tilburg, Netherlands

Local Institution - 580

🇵🇱

Czestochowa, Poland

Local Institution - 988

🇵🇱

Elblag, Poland

Local Institution - 579

🇵🇱

Gdansk, Poland

Local Institution - 978

🇵🇱

Gdansk, Poland

Local Institution - 577

🇵🇱

Gdynia, Poland

Local Institution - 906

🇵🇱

Jelenia Gora, Poland

Local Institution - 757

🇵🇱

Jozefow, Poland

Local Institution - 578

🇵🇱

Katowice, Poland

Local Institution - 834

🇵🇱

Ksawerow, Poland

Local Institution - 581

🇵🇱

Lodz, Poland

Local Institution - 981

🇵🇱

Lodz, Poland

Local Institution - 976

🇵🇱

Nowy Targ, Poland

Local Institution - 963

🇵🇱

Rzeszow, Poland

Local Institution - 979

🇵🇱

Sopot, Poland

Local Institution - 835

🇵🇱

Szczecin, Poland

Local Institution - 586

🇵🇱

Warsaw, Poland

Local Institution - 833

🇵🇱

Warsaw, Poland

Local Institution - 807

🇵🇱

Warsaw, Poland

Local Institution - 989

🇵🇱

Warszawa, Poland

Local Institution - 893

🇵🇱

Wierzchoslawice, Poland

Local Institution - 983

🇵🇱

Wroclaw, Poland

Local Institution - 984

🇵🇱

Wroclaw, Poland

Local Institution - 582

🇵🇱

Wroclaw, Poland

Local Institution - 982

🇵🇱

Wroclaw, Poland

Local Institution - 831

🇵🇱

Wroclaw, Poland

Local Institution - 987

🇵🇱

Wroclaw, Poland

Local Institution - 832

🇵🇱

Wroclaw, Poland

Local Institution - 959

🇵🇹

Coimbra, Portugal

Local Institution - 958

🇵🇹

Guimaraes, Portugal

Local Institution - 961

🇵🇹

Loures, Portugal

Local Institution - 957

🇵🇹

Viana do Castelo, Portugal

Local Institution - 966

🇷🇺

Barnaul, Russian Federation

Local Institution - 871

🇷🇺

Barnaul, Russian Federation

Local Institution - 589

🇷🇺

Bataisk, Russian Federation

Local Institution - 621

🇷🇺

Chelyabinsk, Russian Federation

Local Institution - 991

🇷🇺

Chelyabinsk, Russian Federation

Local Institution - 583

🇷🇺

Ekaterinburg, Russian Federation

Local Institution - 872

🇷🇺

Ekaterinburg, Russian Federation

Local Institution - 998

🇷🇺

Kaliningrad, Russian Federation

Local Institution - 882

🇷🇺

Kaluga, Russian Federation

Local Institution - 849

🇷🇺

Kemerovo, Russian Federation

Local Institution - 566

🇷🇺

Moscow, Russian Federation

Local Institution - 995

🇷🇺

Moscow, Russian Federation

Local Institution - 873

🇷🇺

Moscow, Russian Federation

Local Institution - 870

🇷🇺

Moscow, Russian Federation

Local Institution - 869

🇷🇺

Moscow, Russian Federation

Local Institution - 990

🇷🇺

Nizhny Novgorod, Russian Federation

Local Institution - 853

🇷🇺

Novosibirsk, Russian Federation

Local Institution - 876

🇷🇺

Novosibirsk, Russian Federation

Local Institution - 996

🇷🇺

Omsk, Russian Federation

Local Institution - 875

🇷🇺

Orenburg, Russian Federation

Local Institution - 867

🇷🇺

Penza, Russian Federation

Local Institution - 874

🇷🇺

Saint Petersburg, Russian Federation

Local Institution - 868

🇷🇺

Saint-Petersburg, Russian Federation

Local Institution - 865

🇷🇺

Samara, Russian Federation

Local Institution - 992

🇷🇺

Saratov, Russian Federation

Local Institution - 866

🇷🇺

Sochi, Russian Federation

Local Institution - 878

🇷🇺

St Petersburg, Russian Federation

Local Institution - 863

🇷🇺

St. Petersburg, Russian Federation

Local Institution - 993

🇷🇺

St. Petersburg, Russian Federation

Local Institution - 857

🇷🇺

St. Petersburg, Russian Federation

Local Institution - 879

🇷🇺

St. Petersburg, Russian Federation

Local Institution - 877

🇷🇺

Tomsk, Russian Federation

Local Institution - 881

🇷🇺

Ufa, Russian Federation

Local Institution - 880

🇷🇺

Volgograd, Russian Federation

Local Institution - 546

🇸🇳

Cape Town, Senegal

Local Institution - 887

🇷🇸

Belgrade, Serbia

Local Institution - 596

🇷🇸

Belgrade, Serbia

Local Institution - 886

🇷🇸

Belgrade, Serbia

Local Institution - 890

🇷🇸

Belgrade, Serbia

Local Institution - 891

🇷🇸

Kragujevac, Serbia

Local Institution - 884

🇷🇸

Novi Sad, Serbia

Local Institution - 885

🇷🇸

Pancevo, Serbia

Local Institution - 585

🇷🇸

Vrsac, Serbia

Local Institution - 889

🇷🇸

Zrenjanin, Serbia

Local Institution - 900

🇸🇰

Bratislava, Slovakia

Local Institution - 894

🇸🇰

Bratislava, Slovakia

Local Institution - 895

🇸🇰

Brezno, Slovakia

Local Institution - 899

🇸🇰

Nitra, Slovakia

Local Institution - 897

🇸🇰

Nove Zamky, Slovakia

Local Institution - 898

🇸🇰

Presov, Slovakia

Local Institution - 896

🇸🇰

Rimavska Sobota, Slovakia

Local Institution - 904

🇸🇮

Celje, Slovenia

Local Institution - 543

🇿🇦

Gauteng, South Africa

Local Institution - 545

🇿🇦

Kempton Park, South Africa

Local Institution - 544

🇿🇦

Pretoria, South Africa

Local Institution - 542

🇿🇦

Pretoria, South Africa

Local Institution - 549

🇿🇦

Pretoria, South Africa

Local Institution - 548

🇿🇦

Somerset West, South Africa

Local Institution - 547

🇿🇦

Val De Grace, South Africa

Teknon Medical Center

🇪🇸

Barcelona, Spain

University Hospital Reina Sofia

🇪🇸

Cordoba, Spain

University Hospital of Girona Dr. Josep Trueta

🇪🇸

Girona, Spain

Hospital Universitario De Gran Canaria Dr. Negrin

🇪🇸

Las Palmas de Gran Canaria, Spain

Local Institution - 695

🇪🇸

Madrid, Spain

University Hospital Puerta de Hierro Majadajonda

🇪🇸

Majadahonda, Madrid, Spain

University Hospital Marques de Valdecilla (HUMV)

🇪🇸

Santander, Spain

Local Institution - 697

🇪🇸

Valencia, Spain

Local Institution - 625

🇸🇪

Stockholm, Sweden

Local Institution - 463

🇨🇳

Kaohsiung, San Ming Dist., Taiwan

Local Institution - 460

🇨🇳

Kaohsiung, Taiwan

Local Institution - 461

🇨🇳

Niao-Sung Hsiang Kaohsiung County, Taiwan

Local Institution - 459

🇨🇳

Tainan, Taiana, Taiwan

Local Institution - 462

🇨🇳

Taoyuan City, Taiwan

Local Institution - 464

🇨🇳

Tapei, Beitou Dist., Taiwan

Local Institution - 465

🇨🇳

Tapei, Taiwan

Local Institution - 357

🇹🇷

Ankara, Turkey

Local Institution - 365

🇹🇷

Elazig, Turkey

Local Institution - 358

🇹🇷

Istanbul, Turkey

Local Institution - 361

🇹🇷

Istanbul, Turkey

Local Institution - 353

🇹🇷

Kadiköy/Istanbul, Turkey

Local Institution - 922

🇺🇦

Chernivtsi, Ukraine

Local Institution - 929

🇺🇦

Ivano-Frankivsk, Ukraine

Local Institution - 965

🇺🇦

Kharkiv, Ukraine

Local Institution - 920

🇺🇦

Khmelnytskyi, Ukraine

Local Institution - 933

🇺🇦

Kropyvnytskyi, Ukraine

Local Institution - 923

🇺🇦

Kyiv, Ukraine

Local Institution - 563

🇺🇦

Kyiv, Ukraine

Local Institution - 564

🇺🇦

Kyiv, Ukraine

Local Institution - 977

🇺🇦

Kyiv, Ukraine

Local Institution - 590

🇺🇦

Lutsk, Ukraine

Local Institution - 974

🇺🇦

Lviv, Ukraine

Local Institution - 902

🇺🇦

Odesa, Ukraine

Local Institution - 924

🇺🇦

Vinnytsia, Ukraine

Local Institution - 932

🇺🇦

Vinnytsya, Ukraine

Local Institution - 587

🇺🇦

Zaporizhia, Ukraine

Local Institution - 925

🇺🇦

Zaporizhzhya, Ukraine

© Copyright 2025. All Rights Reserved by MedPath